Liprolog Mix50

Insulin lispro, the active ingredient in Liprolog Mix50, is an insulin analog presented as a solution for subcutaneous use. It treats diabetes mellitus by providing rapid‑acting glucose control in both type 1 and type 2 diabetes patients.

GNH USA supplies Liprolog Mix50 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides reliable cold‑chain logistics for injectable biologics.

Insulin lispro is a rapid‑acting insulin analog used within the diabetes treatment pathway to control post‑prandial blood glucose. - Diabetes mellitus (type 1): provides mealtime insulin coverage to lower post‑prandial glucose. - Diabetes mellitus (type 2): used as part of basal‑bolus regimens to improve overall glycemic control. - Pre‑meal hyperglycemia: rapidly reduces glucose spikes after meals when administered before eating.

Insulin lispro may be associated with a range of adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Hypoglycemia: low blood glucose levels, especially if dose mismatched with carbohydrate intake. - Injection site reactions: redness, swelling, or itching at the injection site. - Lipodystrophy: localized changes in fat tissue with repeated injections. - Weight gain: modest increase in body weight over time. Serious or Rare Side Effects: - Severe hypoglycemia with seizures or loss of consciousness. - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Insulin antibody formation leading to resistance.

When using insulin lispro, careful attention to dosing and monitoring is essential. - Dose adjustment: tailor dose to individual carbohydrate intake, activity level, and blood glucose monitoring. - Hypoglycemia risk: educate patients on recognizing and treating low blood glucose promptly. - Renal impairment: monitor closely as insulin clearance may be reduced. - Pregnancy and lactation: use only if benefits outweigh potential risks; consult healthcare provider. - Concomitant medications: assess for agents that may mask hypoglycemia symptoms. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin lispro can interact with several medicines, affecting glucose control. Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycemia symptoms, requiring closer glucose monitoring. - MAO inhibitors: can potentiate insulin’s hypoglycemic effect, increasing risk of severe low blood sugar. Moderate Interactions (Monitor Closely): - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides): additive glucose‑lowering effect, may need dose reduction. - Corticosteroids: can raise blood glucose, potentially requiring higher insulin doses. - Alcohol: can cause delayed hypoglycemia, especially when combined with rapid‑acting insulin.